Posted by rob on December 29, 2010 under Uncategorized | 
Tumor-specific Cytotoxicity and Type of Cell Death Induced by Benzaldehyde.
Anticancer Res. 2010 Dec;30(12):5069-76
Authors: Ariyoshi-Kishino K, Hashimoto K, Amano O, Saitoh J, Kochi M, Sakagami H
We have previously reported that sodium 5,6-benzylidene-L-ascorbate (SBA) induced dramatic antitumor activity in inoperable cancer patients, but induced only marginal tumor specificity in vitro. Here the tumor specificity and type of cell death induced by benzaldehyde (BA), a degradation product of SBA, was investigated, using human tumor cell lines (oral squamous cell carcinoma [OSCC], glioblastoma, myelogenous leukemia) and human normal oral cells (gingival fibroblast, pulp cell, periodontal ligament fibroblast). BA showed much higher tumor-specific cytotoxicity than SBA. BA induced the formation of autophagosomes, the destruction of mitochondrial structure and digestion of broken organelles, without any apparent induction of internucleosomal DNA fragmentation and caspase activation in an OSCC cell line HSC-2, in a similar manner to SBA. However, pretreatment with 3-methyladenine or bafilomycin A(1), autophagy inhibitors, did not completely rescue the cells from the cytotoxicity induced by BA. The study suggests that BA may play an important role in the induction of antitumor activity of SBA in vivo, although the autophagic phenotypes induced by BA may be involved in both cell death and survival.
PMID: 21187492 [PubMed - in process]
More
Posted by rob on under Uncategorized |
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.
BMC Med Genet. 2010;11:163
Authors: Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O’Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M
Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS.
PMID: 21078205 [PubMed - indexed for MEDLINE]
More
Posted by rob on under Uncategorized |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Am J Hematol. 2010 Dec;85(12):960-3
Authors: Visani G, Breccia M, Gozzini A, Specchia G, Montefusco E, Morra E, Annunziata M, Camera A, Cavazzini F, Stagno F, Pregno P, Usala E, Santini V, Piccaluga PP, Isidori A
PMID: 21069865 [PubMed - indexed for MEDLINE]
More
Posted by rob on under Uncategorized |
[Leukemia and lymphoma].
Nippon Rinsho. 2010 Aug;68 Suppl 8:481-4
Authors: Kato M, Ogawa S
PMID: 20979299 [PubMed - indexed for MEDLINE]
More
Posted by rob on under Uncategorized |
An asymptomatic 61-year-old man with BCR-ABL-positive bone marrow following autologous transplantation for multiple myeloma.
Am J Hematol. 2010 Dec;85(12):944-6
Authors: Roper N, DeAngelo DJ, Kuo F, Dal Cin P, Ghobrial I, Aster JC
PMID: 20730794 [PubMed - indexed for MEDLINE]
More
Posted by rob on under Uncategorized |
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Bone Marrow Transplant. 2010 Sep;45(9):1469-70
Authors: Pulanic D, Cowen EW, Baird K, Bishop MR, Pavletic SZ
PMID: 20062096 [PubMed - indexed for MEDLINE]
More
